Market analysts project the GLP-1 receptor agonist aesthetic care segment—driven by semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound)—will reach $2 billion by 2030. The category encompasses direct GLP-1 prescribing, skin-tightening treatments for post-weight-loss patients, and complementary injectables and energy-device procedures.
Market
GLP-1 Aesthetic Care Market Projected to Reach $2B by 2030
Semaglutide-driven weight loss opens new revenue stream for medspas and aesthetic practices.
GLP-1 aesthetic care projected to hit $2B by 2030, creating new revenue streams for practices offering weight-loss and skin-tightening services.
For medspas, the opportunity is two-fold: first, direct GLP-1 prescribing under appropriate medical supervision and state scope-of-practice rules; second, capturing the downstream aesthetic demand from patients experiencing rapid weight loss. Post-weight-loss skin laxity drives demand for monopolar RF (Morpheus8), fractional ablative systems, and biostimulators (Radiesse, Sculptra). Practices positioned to offer both GLP-1 management and aesthetic body contouring will capture higher lifetime patient value. The risk: regulatory scrutiny around GLP-1 prescribing in non-medical settings, and competition from primary-care and telehealth providers entering the space.
Source: original report ↗
Free alerts
Free: recall & rule-change alerts for your practice.
Get the recalls and state-law changes that hit your treatment room, in your inbox — free. Unsubscribe in one click.
Free · weekly · unsubscribe anytime. Privacy.
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Inside MedSpa Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.
Get the edge · $20/moJoin the owners who run ahead of the industry. Cancel anytime, one click.